147 related articles for article (PubMed ID: 35831917)
1. Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
Liu K; Zheng W; Chen Y; Tang M; Li D; Deng D; Yang T; Zhang C; Liu J; Yuan X; Shi M; Li X; Guo Y; Zhou Y; Zhao M; Chen L
J Med Chem; 2022 Jul; 65(14):9893-9917. PubMed ID: 35831917
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.
Zhou H; McGowan MA; Lipford K; Christopher M; Fradera X; Witter D; Lesburg CA; Li C; Methot JL; Lampe J; Achab A; Shaffer L; Goldenblatt P; Shah S; Bass A; Schroeder G; Chen D; Zeng H; Augustin MA; Katz JD
Bioorg Med Chem Lett; 2020 Jan; 30(1):126715. PubMed ID: 31757666
[TBL] [Abstract][Full Text] [Related]
4. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
[TBL] [Abstract][Full Text] [Related]
5. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
Zhang J; Jiang H; Lin S; Wu D; Tian H; Jiang L; Cui Y; Jin J; Chen X; Xu H
J Med Chem; 2022 Jun; 65(11):8011-8028. PubMed ID: 35609190
[TBL] [Abstract][Full Text] [Related]
6. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
7. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma.
Qi J; Wang W; Tang Y; Lou S; Wang J; Yuan T; He Q; Yang B; Zhu H; Cui S
J Med Chem; 2022 Mar; 65(5):3849-3865. PubMed ID: 35191698
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a Potent and Selective PI3Kδ Inhibitor (
Shukla MR; Patra S; Verma M; Sadasivam G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Tarage A; Cheemala M; Kulkarni C; Bhagwat S; Chaudhari VD; Sayyed M; Pachpute V; Phadtare R; Gole G; Phukan S; Sunkara B; Samant C; Shingare M; Naik A; Trivedi S; Marisetti AK; Reddy M; Gholve M; Mahajan N; Sabde S; Patil V; Modi D; Mehta M; Nigade P; Tamane K; Tota S; Goyal H; Volam H; Pawar S; Ahirrao P; Dinchhana L; Mallurwar S; Akarte A; Bokare A; Kanhere R; Reddy N; Koul S; Dandekar M; Singh M; Bernstein PR; Narasimham L; Bhonde M; Gundu J; Goel R; Kulkarni S; Sharma S; Kamboj RK; Palle VP
J Med Chem; 2020 Dec; 63(23):14700-14723. PubMed ID: 33297683
[TBL] [Abstract][Full Text] [Related]
10. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
[TBL] [Abstract][Full Text] [Related]
11. 2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors.
Patel L; Chandrasekhar J; Evarts J; Haran AC; Ip C; Kaplan JA; Kim M; Koditek D; Lad L; Lepist EI; McGrath ME; Novikov N; Perreault S; Puri KD; Somoza JR; Steiner BH; Stevens KL; Therrien J; Treiberg J; Villaseñor AG; Yeung A; Phillips G
J Med Chem; 2016 Apr; 59(7):3532-48. PubMed ID: 26980109
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.
Bai H; Sun J; Lei H; Zhang SQ; Yuan B; Ma M; Xin M
Drug Dev Res; 2023 Dec; 84(8):1709-1723. PubMed ID: 37732677
[TBL] [Abstract][Full Text] [Related]
13. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments.
Lei H; Duan W; Zhang SQ; Feng Y; Ma M; Yuan B; Xin M
Bioorg Chem; 2023 Sep; 138():106594. PubMed ID: 37186998
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
Gong YP; Tang LQ; Liu TS; Liu ZP
Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
[TBL] [Abstract][Full Text] [Related]
17. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
Moreno O; Wood J
Target Oncol; 2019 Oct; 14(5):603-611. PubMed ID: 31506873
[TBL] [Abstract][Full Text] [Related]
18. Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
Liu L; Li X; Cheng Y; Wang L; Yang H; Li J; He S; Shuangjie Wu ; Yin Q; Xiang H
Eur J Med Chem; 2019 Feb; 164():304-316. PubMed ID: 30605829
[TBL] [Abstract][Full Text] [Related]
19. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis.
Yu M; Wang X; Tang Y; Wang L; Hu X; Weng Q; Wang J; Cui S
J Med Chem; 2024 Jun; 67(11):9628-9644. PubMed ID: 38754045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
